IntroductionMany adults with current impairing symptoms of attention-deficit/hyperactivity
disorder (ADHD) do not report an age at onset before 7 years of age and cannot, therefore …

Poor adherence is a major concern in the treatment of attention-deficit/hyperactivity disorder
(ADHD). The objective of this study was to evaluate factors linked to early interruption of and …

Objectives This study evaluated neurocognitive changes after switching from immediate
release forms of methylphenidate (MPH‐IR) to osmotic release oral system methylphenidate …

Objective: The aim of this study was to compare the pharmacokinetics of immediate-release
methylphenidate (MPH) in preschool and school-aged children with attention …

This study evaluated the efficacy and tolerability in the initiation treatment of
Concerta®(OROS methylphenidate HCl) in Korean children with Attention …

Methylphenidate is used for the treatment of attention deficit hyperactivity disorder (ADHD).
OROS®(methylphenidate HCl) is an osmotic controlled‐release delivery system designed …

Objective: To examine the pharmacokinetics (PKs) and pharmacodynamics (PDs) of
OROS® methylphenidate (OROS MPH) dosed once daily (QD) versus an early standard …

Objective: To compare the dose effects of long-acting extended-release dexmethylphenidate
(ER d-MPH) and ER mixed amphetamine salts (ER MAS) on attention-deficit/hyperactivity …

Background To evaluate health-related quality of life (HRQL) and medication satisfaction
after switching from a stable dose of oral extended-release methylphenidate (ER-MPH) to …

Objective: To examine the effectiveness of four doses of psychostimulant medication,
combining extended-release methylphenidate (ER-MPH) in the morning with immediate …